Vaxart Inc VXRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.58
- Day Range
- $0.55–0.57
- 52-Week Range
- $0.31–0.84
- Bid/Ask
- $0.57 / $0.57
- Shares Outstanding
- 242.04M
- Market Cap
- $138.52M
- Volume/Avg
- 29,949 / 337,316
Key Statistics
- Price/Earnings (Normalized)
- 3.45
- Price/Sales
- 0.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 65
- Website
- https://www.vaxart.com
Valuation
|
Metric
|
VXRT
|
|---|---|
Price/Earnings (Normalized) | 3.45 |
Price/Book Value | 1.69 |
Price/Sales | 0.56 |
Price/Cash Flow | 2.62 |
Price/Earnings
VXRT
Financial Strength
|
Metric
|
VXRT
|
|---|---|
Quick Ratio | 1.52 |
Current Ratio | 1.60 |
Interest Coverage | 17.85 |
Quick Ratio
VXRT
Profitability
|
Metric
|
VXRT
|
|---|---|
Return on Assets (Normalized) | 24.89% |
Return on Equity (Normalized) | 69.50% |
Return on Invested Capital (Normalized) | 59.49% |
Return on Assets
VXRT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|M!$$Wp! | LOCK|$#N& | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|c@p@PYp | LOCK|%Pq!? | $83B | |||
| argenx SE ADR
ARGX
| LOCK|r!SB#Ry | LOCK|HP | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>Y^%F>D> | LOCK|$!z<^ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|J?!Wcgj | LOCK|G!$ | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|l%^>!>^ | LOCK|#r&J | $29B | |||
| Incyte Corp
INCY
| LOCK|!ZKW### | LOCK|@$m | $25B | |||
| Moderna Inc
MRNA
| LOCK|k@rFbf | LOCK|k# | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|!BxC@$ | LOCK|>?v | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^N#V^Dn | LOCK|%r? | $17B |
United States